1.95 USD
-0.02 (-1.02%)
1.9672 USD
+0.02 (+0.88%)
DARE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of DARE have multiple concerns. DARE has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- DARE had negative earnings in the past year.
- In the past year DARE has reported a negative cash flow from operations.
- In the past 5 years DARE always reported negative net income.
- In the past 5 years DARE reported 4 times negative operating cash flow.
1.2 Ratios
- With a decent Return On Assets value of -13.18%, DARE is doing good in the industry, outperforming 63.35% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -141.84%, DARE is doing worse than 69.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.18% | ||
| ROE | -141.84% | ||
| ROIC | N/A |
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- DARE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- DARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, DARE has more shares outstanding
- Compared to 5 years ago, DARE has less shares outstanding
- The debt/assets ratio for DARE is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -10.29, we must say that DARE is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of DARE (-10.29) is worse than 73.82% of its industry peers.
- A Debt/Equity ratio of 1.88 is on the high side and indicates that DARE has dependencies on debt financing.
- With a Debt to Equity ratio value of 1.88, DARE is not doing good in the industry: 77.49% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.88 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.29 |
ROIC/WACCN/A
WACC9.21%
2.3 Liquidity
- A Current Ratio of 1.18 indicates that DARE should not have too much problems paying its short term obligations.
- With a Current ratio value of 1.18, DARE is not doing good in the industry: 81.15% of the companies in the same industry are doing better.
- DARE has a Quick Ratio of 1.18. This is a normal value and indicates that DARE is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.18, DARE is not doing good in the industry: 74.87% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
- DARE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -218.64%.
- DARE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.65%.
EPS 1Y (TTM)-218.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.09%
Revenue 1Y (TTM)-99.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, DARE will show a very strong growth in Earnings Per Share. The EPS will grow by 71.78% on average per year.
- DARE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 188.14% yearly.
EPS Next Y-203.06%
EPS Next 2Y62.1%
EPS Next 3Y76.01%
EPS Next 5Y71.78%
Revenue Next Year-72.64%
Revenue Next 2Y390.72%
Revenue Next 3Y261.34%
Revenue Next 5Y188.14%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- DARE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- A Price/Forward Earnings ratio of 5.97 indicates a rather cheap valuation of DARE.
- Based on the Price/Forward Earnings ratio, DARE is valued cheaply inside the industry as 93.19% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 24.26. DARE is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.97 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- DARE's earnings are expected to grow with 76.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y62.1%
EPS Next 3Y76.01%
5. Dividend
5.1 Amount
- No dividends for DARE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
DARE BIOSCIENCE INC / DARE FAQ
Can you provide the ChartMill fundamental rating for DARE BIOSCIENCE INC?
ChartMill assigns a fundamental rating of 2 / 10 to DARE.
Can you provide the valuation status for DARE BIOSCIENCE INC?
ChartMill assigns a valuation rating of 3 / 10 to DARE BIOSCIENCE INC (DARE). This can be considered as Overvalued.
How profitable is DARE BIOSCIENCE INC (DARE) stock?
DARE BIOSCIENCE INC (DARE) has a profitability rating of 1 / 10.
How financially healthy is DARE BIOSCIENCE INC?
The financial health rating of DARE BIOSCIENCE INC (DARE) is 1 / 10.